Does Schizophrenia Get Worse with Age? What Research Shows

No, Schizophrenia does not inevitably worsen with age.

The clinical picture is more nuanced and more optimistic than commonly assumed. Research consistently shows that positive symptoms including hallucinations and delusions often diminish in intensity in midlife and beyond. While cognitive deficits and negative symptoms including social withdrawal and emotional blunting tend to remain stable or show modest decline, particularly in individuals without adequate treatment continuity.

The most important determinant of schizophrenia’s trajectory across the lifespan is not age alone but access to sustained, evidence-based treatment and the presence or absence of substance use disorder as a co-occurring comorbidity.

Key Takeaways

• Schizophrenia does not follow a simple progressive deterioration course; longitudinal studies show positive symptom improvement in a significant proportion of patients over decades, while negative symptoms and cognitive deficits show more variable trajectories.
• Approximately 20 to 25 percent of individuals with schizophrenia achieve substantial symptomatic recovery by midlife, according to long-term longitudinal studies including the Vermont Longitudinal Research Project.
• Co-occurring substance use disorder, present in approximately 50 percent of people with schizophrenia, is the strongest modifiable predictor of symptom worsening and poor long-term outcome independent of age.
• The DSM-5-TR defines schizophrenia by positive symptoms (hallucinations, delusions, disorganized speech), negative symptoms (diminished emotional expression, avolition), and cognitive deficits as the primary domains, with course specifiers indicating whether the disorder is continuous, episodic, or in partial or full remission.
• Late-onset schizophrenia (onset after age 40) and very-late-onset schizophrenia-like psychosis (onset after age 60) represent distinct presentations with different neurobiological substrates and different age-related trajectories from early-onset schizophrenia.

What Is Schizophrenia?

Schizophrenia is a chronic psychotic disorder defined in the DSM-5-TR by the presence of at least two of five characteristic symptoms for a significant portion of a one-month period, with continuous signs of disturbance for at least six months. It is classified as a spectrum condition alongside schizoaffective disorder, schizophreniform disorder, and brief psychotic disorder in the DSM-5-TR Schizophrenia Spectrum chapter.

DSM-5-TR Diagnostic Criteria: Three Symptom Domains

• Positive symptoms: Hallucinations (most commonly auditory), delusions (fixed false beliefs), disorganized thinking manifesting as tangential or incoherent speech, and grossly disorganized or catatonic behavior
• Negative symptoms: Diminished emotional expression (flat affect), alogia (reduced speech output), avolition (inability to initiate and sustain goal-directed activity), anhedonia, and asociality
• Cognitive deficits: Working memory impairment, reduced processing speed, executive function deficits, and attention problems that predate first psychotic episode onset and persist regardless of positive symptom status

Does Schizophrenia Get Worse with Age?

The longitudinal research on schizophrenia’s age-related trajectory contradicts the historically dominant view of inevitable progressive deterioration, replacing it with a more heterogeneous picture in which outcome is highly variable and modifiable.

Positive Symptoms: Tend to Improve in Later Life

Dr. Courtenay Harding’s Vermont Longitudinal Research Project, one of the longest-running schizophrenia outcome studies, followed patients for 22 to 62 years and found that 50 to 66 percent showed significant improvements or recovery in positive symptoms by late midlife. Hallucination intensity and delusional conviction frequently diminish after age 45 to 50 in patients who remain engaged with treatment, a finding replicated across multiple international longitudinal cohorts.

• Why positive symptoms may improve with age: Declining dopaminergic activity in mesolimbic pathways with normal aging reduces the dopamine dysregulation that drives positive symptom generation; some researchers describe this as a “natural antipsychotic effect” of age-related dopamine system changes
• Caveat: Positive symptom improvement is not uniform; patients who discontinue antipsychotic medication, experience multiple relapses, or have co-occurring substance use disorder show less improvement with aging

Negative Symptoms and Cognitive Deficits: More Persistent

While positive symptoms often improve, negative symptoms (avolition, flat affect, alogia, asociality) and cognitive deficits show more variable and generally less favorable age-related trajectories, reflecting their different neurobiological substrates in prefrontal cortex glutamatergic systems rather than mesolimbic dopaminergic circuits.

• Negative symptoms in older adults: Flat affect and avolition tend to be stable across adulthood in treated patients but can worsen with untreated depression, social isolation, or medication side effects that mimic or amplify negative symptoms
• Cognitive decline in late life: Adults with schizophrenia show accelerated cognitive aging in some domains, with processing speed and working memory declining faster than in the general population after age 65, though not necessarily at dementia levels
• Late-life dementia risk: Meta-analytic data suggests schizophrenia is associated with a modestly elevated dementia risk in very late life; however, this association is confounded by medication effects, smoking rates, and metabolic syndrome prevalence in schizophrenia populations

Schizophrenia Course Specifiers in the DSM-5-TR

The DSM-5-TR acknowledges schizophrenia’s variable trajectory by requiring course specifiers at the one-year mark: first episode currently in acute episode; first episode currently in partial or full remission; multiple episodes currently in acute episode; multiple episodes currently in partial or full remission; and continuous course. These specifiers reflect the research reality that schizophrenia is not uniformly chronic or uniformly progressive.

What Makes Schizophrenia Worse?

While age alone does not determine schizophrenia’s trajectory, several modifiable and non-modifiable factors consistently predict worse outcomes across the lifespan.

Substance Use Disorder: The Strongest Modifiable Risk Factor

Co-occurring substance use disorder, present in approximately 47 to 50 percent of people with schizophrenia (SAMHSA NSDUH data), is the single strongest modifiable predictor of symptom exacerbation, hospitalization, medication non-adherence, and poor long-term outcome. Cocaine, cannabis, and stimulant use disorder each independently worsen positive symptoms through dopaminergic dysregulation mechanisms that directly interact with schizophrenia’s neurobiological substrate.

• Cannabis: THC produces dose-dependent mesolimbic dopamine release and CB1 receptor activation in prefrontal cortex; in schizophrenia, this amplifies the dopaminergic dysregulation driving hallucinations and delusions and is associated with earlier psychosis onset and more frequent relapses
• Stimulants: Cocaine and methamphetamine increase synaptic dopamine through reuptake inhibition and reverse transport; both agents reliably worsen psychotic symptoms and produce prolonged post-use psychosis periods in schizophrenia patients
• Alcohol: Heavy alcohol use disorder worsens medication adherence, impairs executive function independently, and increases the risk of comorbid depressive episodes that worsen the overall clinical picture

Antipsychotic Non-Adherence

Medication non-adherence is strongly associated with relapse, symptom exacerbation, and progressive cognitive decline. Each psychotic relapse episode is associated with modest but measurable changes in hippocampal volume and white matter integrity that accumulate over multiple episodes, providing a neurobiological mechanism for relapse-driven deterioration independent of aging.

Social Isolation and Institutional Factors

Social isolation, poverty, homelessness, and incarceration all independently worsen schizophrenia outcomes through stress-axis activation, reduced access to medication, and loss of social support structures that buffer against relapse. These social determinants of health disproportionately affect schizophrenia populations and account for a significant portion of the outcome variance attributed to the disorder itself.

Co-Occurring Schizophrenia and Substance Use Disorder: Treatment at Riverside Recovery of Tampa

Co-occurring schizophrenia and substance use disorder requires integrated dual diagnosis treatment that addresses both conditions simultaneously. At Riverside Recovery of Tampa’s dual diagnosis program, psychiatric evaluation and stabilization is integrated within the addiction treatment continuum, ensuring that co-occurring psychotic disorders receive appropriate assessment and pharmacological management alongside substance use disorder treatment.

Assistant Medical Director Erin Ikenberry, PA-C, notes: “Schizophrenia and substance use disorder are such a common pairing that we see it regularly. The challenge is that untreated or undertreated psychosis makes addiction treatment participation extremely difficult, and active substance use makes psychosis harder to treat. Both conditions need to be addressed together from day one.”

Residential treatment provides the structured, substance-free environment in which psychiatric stabilization on antipsychotic therapy can proceed without the interference of active substance use. Evidence-based therapy adapted for psychosis and substance use disorder, including modified CBT approaches, builds coping skills compatible with schizophrenia’s cognitive profile. Step-down through IOP and all programs available with same-day assessment at (800) 871-5440.

Frequently Asked Questions

Does schizophrenia get worse with age?

Not inevitably. Research shows positive symptoms like hallucinations and delusions often improve in midlife, while negative symptoms and cognitive deficits are more stable. Approximately 20 to 25 percent of people with schizophrenia achieve substantial symptomatic recovery by midlife. The strongest predictor of worsening is substance use disorder and medication non-adherence, not age itself.

What happens to schizophrenia in old age?

In older adults, schizophrenia’s positive symptoms often stabilize or improve with declining mesolimbic dopamine activity. Cognitive function may show accelerated decline after age 65 compared to the general population. Social functioning, housing stability, and physical health comorbidities become increasingly important determinants of quality of life and functional outcome in older adults with schizophrenia.

Can schizophrenia go into remission?

Yes. The DSM-5-TR includes partial and full remission course specifiers for schizophrenia. Research including the Vermont Longitudinal Research Project shows 50 to 66 percent of patients demonstrate significant symptom improvement over decades. Sustained antipsychotic treatment, social support, and absence of substance use disorder are the key predictors of sustained remission.

What makes schizophrenia symptoms worse?

The main modifiable factors that worsen schizophrenia are: substance use disorder (especially cannabis, stimulants, and cocaine), antipsychotic medication non-adherence, social isolation and lack of support, psychosocial stress, and sleep disruption. Each psychotic relapse episode is associated with cumulative neurobiological changes that may worsen long-term cognitive outcomes.

Is late-onset schizophrenia different from early-onset?

Yes. Late-onset schizophrenia (onset after age 40) and very-late-onset schizophrenia-like psychosis (onset after 60) have distinct presentations: more auditory hallucinations, fewer formal thought disorder features, better preserved cognitive function, and better antipsychotic response than early-onset cases. They may reflect different neurobiological substrates including estrogen decline in women and neurodegenerative processes rather than the developmental neurodisconnection of early-onset schizophrenia.

Does schizophrenia cause dementia?

Schizophrenia is associated with cognitive decline and modestly elevated dementia risk in very late life compared to the general population. However, the relationship is complex and confounded by high smoking rates, antipsychotic metabolic effects, and social determinants. The cognitive deficits of schizophrenia are distinct from Alzheimer’s pathology and do not inevitably progress to dementia, though older adults with schizophrenia require monitoring for emerging neurodegenerative changes.

References

1. Harding, C. M., Brooks, G. W., Ashikaga, T., Strauss, J. S., & Breier, A. (1987). The Vermont longitudinal study of persons with severe mental illness. American Journal of Psychiatry, 144(6), 718–726.
2. Jobe, T. H., & Harrow, M. (2005). Long-term outcome of patients with schizophrenia: A review. Canadian Journal of Psychiatry, 50(14), 892–900.
3. Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009). Psychiatric comorbidities and schizophrenia. Schizophrenia Bulletin, 35(2), 383–402.
4. Substance Abuse and Mental Health Services Administration. (2023). National Survey on Drug Use and Health, 2022 results. U.S. Department of Health and Human Services.
5. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.
6. Harvey, P. D. (2019). Domains of cognition and their assessment. Dialogues in Clinical Neuroscience, 21(3), 227–237.
7. National Institute of Mental Health. (2023). Schizophrenia. Retrieved from nimh.nih.gov